A1416612
Bosutinib (SKI-606) , ≥99% , 380843-75-4
Synonym(s):
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;SKI-606;WAY-173606
CAS NO.：380843-75-4
Empirical Formula: C26H29Cl2N5O3
Molecular Weight: 530.45
MDL number: MFCD07367846
EINECS: 700-455-1
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB286.40 | In Stock |
|
| 50MG | RMB632.00 | In Stock |
|
| 100MG | RMB817.60 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 116-120 ºC |
| Boiling point: | 649.7±55.0 °C(Predicted) |
| Density | 1.36 |
| vapor pressure | 0-0Pa at 20℃ |
| storage temp. | room temp |
| solubility | DMSO: ≥15mg/mL |
| form | powder |
| pka | 7.63±0.10(Predicted) |
| color | off-white to light brown |
| Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
| InChIKey | PICKMQXYAMDEPF-UHFFFAOYSA-N |
| LogP | 3.3-4.3 at pH9.5 |
| Surface tension | 72.4mN/m at 3.6mg/L and 20℃ |
Description and Uses
Bosutinib, similar to dasatinib, was developed as a dual inhibitor of the SCR family of kinases and the ABL kinase, thus applicable for Ph+ leukemias. In September 2012, the US FDA approved bosutinib (also referred to as SKI-607) for the treatment of relapsed or refractory chronicmyeloid leukemia (CML) for patients with resistance or intolerance to prior therapy.
A novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
